“At a business level the deal made great strategic sense,” said Cooley Godward partner Keith Flaum, who represented South San Francisco-based Cor in the merger. Millennium is a research and development “machine that’s great at finding products and developing relationships” while Cor has a cardiovascular product on the market.
Millennium, based in Cambridge, Mass., has focused in the areas of oncology, inflammation and metabolic disease. The company markets two products, Campath, for the treatment of B-cell chronic lymphocytic leukemia, and Melastatin, a diagnostic for determining the risk of skin cancer.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]